Leukopenia, diarrhea, neutropenia, proteinuria, increased aspartate aminotransferase, stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase, hypertension, decreased weight, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache were the most commonly observed AEs with aflibercept (all grades ≥20% incidence, ≥2% between arm difference). This evidence concerns the gene GPT and neutropenia.